Dr. Jeff Sherman, MD, FACP
Board Member
Jeffrey (Jeff) Sherman brings more than 35 years of biopharmaceutical experience, specializing in clinical and regulatory strategy, and therapeutic development of medicines for rare diseases as a board member of the Center for Healthcare Innovation (CHI). He served as Chief Medical Officer (CMO) now Emeritus at Horizon Therapeutics now Amgen (Rare Disease). Dr. Sherman joined Horizon Therapeutics in 2009 from IDM Pharma where he served as Senior Vice President of Research and Development and CMO. At IDM Pharma, he led the clinical, regulatory, and development teams that secured European Commission approval for MEPACT® (mifamurtide), a treatment for osteosarcoma. Prior to IDM Pharma, Dr. Sherman was Vice President of Clinical Science at Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited. Dr. Sherman was also CMO and Executive Vice President at NeoPharm, Inc., held numerous clinical research and development and medical affairs roles at Searle/Pharmacia, and clinical pharmacology and clinical research and development roles at Squibb/Bristol-Myers Squibb.
He is a member of a number of professional societies, a board member of the Center for Healthcare Innovation (CHI), a member of the board of advisors of the Center for Information and Study on Clinical Research Participation (CISCRP), a past steering committee member of the FDA sponsored Clinical Trial Transformation Initiative (CTTI), chair of the scientific advisory board of Cures Within Reach, a former board chairperson and now inaugural fellow of the Drug Information Association (DIA), a member of the board of the Erie Family Health Foundation, a former member of the Global Genes Medical and Scientific Advisory Board, and involved with the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS). He has served as an Adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine and is a member of the executive committee of the alumni board, an advisory board member of the Stanford University School of Medicine Master of Science in Translational Research and Applied Medicine (MTRAM) program, and a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. Dr. Sherman also serves on the boards of directors of Larimar Therapeutics, Sorriso Pharmaceuticals, and Xeris Biopharma Holdings.
Dr. Sherman received his medical degree from the Chicago Medical School at Rosalind Franklin University of Medicine and Science and completed an internal medicine internship, residency, and chief medical residency at Northwestern University. His fellowship training was at the University of California, San Francisco, where he was also a research associate at the Howard Hughes Medical Institute.